154 related articles for article (PubMed ID: 35433426)
1. Case Report: Molecular Profiling Assists in the Diagnosis and Treatment of Cancer of Unknown Primary.
Yu B; Wang Q; Liu X; Hu S; Zhou L; Xu Q; Sun Y; Hu X; Luo Z; Zhang X
Front Oncol; 2022; 12():723140. PubMed ID: 35433426
[TBL] [Abstract][Full Text] [Related]
2. Cancer of unknown primary with EGFR mutation successfully treated with targeted therapy directed by clinical next-generation sequencing: a case report.
Mitani Y; Kanai M; Kou T; Kataoka S; Doi K; Matsubara J; Ohashi S; Matsumoto S; Muto M
BMC Cancer; 2020 Dec; 20(1):1177. PubMed ID: 33267781
[TBL] [Abstract][Full Text] [Related]
3. Immunochemotherapy achieved a complete response for metastatic adenocarcinoma of unknown primary based on gene expression profiling: a case report and review of the literature.
Sheng J; Pan H; Han W
Front Immunol; 2023; 14():1181444. PubMed ID: 37153561
[TBL] [Abstract][Full Text] [Related]
4. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
Masuda N; Ohtani S; Takano T; Inoue K; Suzuki E; Nakamura R; Bando H; Ito Y; Ishida K; Yamanaka T; Kuroi K; Yasojima H; Kasai H; Takasuka T; Sakurai T; Kataoka TR; Morita S; Ohno S; Toi M
Breast Cancer Res Treat; 2020 Feb; 180(1):135-146. PubMed ID: 31953696
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
6. Overview of various techniques/platforms with critical evaluation of each.
Agwa E; Ma PC
Curr Treat Options Oncol; 2013 Dec; 14(4):623-33. PubMed ID: 24243164
[TBL] [Abstract][Full Text] [Related]
7. Cancer of Unknown Primary: A Review on Clinical Guidelines in the Development and Targeted Management of Patients with the Unknown Primary Site.
Qaseem A; Usman N; Jayaraj JS; Janapala RN; Kashif T
Cureus; 2019 Sep; 11(9):e5552. PubMed ID: 31695975
[TBL] [Abstract][Full Text] [Related]
8. The diagnosis and treatment for a patient with cancer of unknown primary: A case report.
Hu H; Pan Q; Shen J; Yao J; Fu G; Tian F; Yan N; Han W
Front Genet; 2023; 14():1085549. PubMed ID: 36741314
[No Abstract] [Full Text] [Related]
9. The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary
Dermawan JK; Rubin BP
Semin Diagn Pathol; 2021 Nov; 38(6):193-198. PubMed ID: 33309276
[TBL] [Abstract][Full Text] [Related]
10. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
Hainsworth JD; Rubin MS; Spigel DR; Boccia RV; Raby S; Quinn R; Greco FA
J Clin Oncol; 2013 Jan; 31(2):217-23. PubMed ID: 23032625
[TBL] [Abstract][Full Text] [Related]
11. The practical utility of AI-assisted molecular profiling in the diagnosis and management of cancer of unknown primary: an updated review.
Lorkowski SW; Dermawan JK; Rubin BP
Virchows Arch; 2024 Feb; 484(2):369-375. PubMed ID: 37999736
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment using immunotherapy in combination with chemotherapy for metastatic squamous cell carcinoma of unknown primary origin with bulky abdominal mass: A case report.
Zhang M; Zhao M; Jin LF; Shen WZ
Medicine (Baltimore); 2021 Dec; 100(48):e28074. PubMed ID: 35049231
[TBL] [Abstract][Full Text] [Related]
13. Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary.
Shih J; Bashir B; Gustafson KS; Andrake M; Dunbrack RL; Goldstein LJ; Boumber Y
J Natl Compr Canc Netw; 2015 Aug; 13(8):947-52. PubMed ID: 26285240
[TBL] [Abstract][Full Text] [Related]
14. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
[TBL] [Abstract][Full Text] [Related]
15. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
16. Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management.
Greco FA
Curr Treat Options Oncol; 2013 Dec; 14(4):634-42. PubMed ID: 23990214
[TBL] [Abstract][Full Text] [Related]
17. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.
Tothill RW; Li J; Mileshkin L; Doig K; Siganakis T; Cowin P; Fellowes A; Semple T; Fox S; Byron K; Kowalczyk A; Thomas D; Schofield P; Bowtell DD
J Pathol; 2013 Dec; 231(4):413-23. PubMed ID: 24037760
[TBL] [Abstract][Full Text] [Related]
18. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
Ross JS; Sokol ES; Moch H; Mileshkin L; Baciarello G; Losa F; Beringer A; Thomas M; Elvin JA; Ngo N; Jin DX; Krämer A
Oncologist; 2021 Mar; 26(3):e394-e402. PubMed ID: 33219618
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
